Spruce Biosciences
South San Francisco, California, United States · Biotechnology
Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company aims to address significant unmet medical needs through innovative treatment solutions. Spruce has a particular focus on rare diseases and is committed to serving patient communities. They are known for their work in enzyme replacement
Key facts
- Headquarters
- South San Francisco, California, United States
- Employees
- 20
- Industries
- Biotechnology
- Status
- Public (SPRB)
- Website
- sprucebio.com
- Company page
Recent activity at Spruce Biosciences
- : SEC 8-K (5.02): On July 27, 2026, Spruce Biosciences, Inc. appointed Adrian Quartel, M.D., FFPM, as the Chief Medical Officer, replacing Dr. Kirk Ways, who will remain on the Board of Directors. Dr. Quartel is a seasoned professional with over 25 years of experience in the pharmaceutical industry, noted for his roles in clinical development and medical affairs, particularly in enzyme replacement therapies for rare diseases. His prior experience includes serving as Chief Medical Officer at Zevra Therapeutics, and he has been instrumental in the development of several rare disease treatments. The transition signifies a strategic move to strengthen the company’s leadership in the rare disease sector.
- : Spruce Biosciences Appoints Agnieszka Jurecka as Vice President of Medical Affairs
- : SEC 8-K (1.01): On April 20, 2026, Spruce Biosciences, Inc. entered into an underwriting agreement with Leerink Partners LLC, Guggenheim Securities, LLC, and Oppenheimer & Co. Inc. to issue and sell 1,150,000 shares of common stock at a public price of $50.00 per share, along with pre-funded warrants for 50,000 shares at $49.99 each. The offering, resulting in gross proceeds of approximately $69.0 million, was made under registration statement Form S-3 and is expected to close on April 22, 2026. The agreement includes a 30-day option for underwriters to purchase up to an additional 180,000 shares, exercised on April 21, 2026, along with customary terms and conditions typical of such agreements.
- : SEC 8-K (1.02):
- : SEC 8-K (5.02): On March 9, 2026, the Company appointed Corwin Dale Hooks as its Chief Commercial Officer, effective the same day. Mr. Hooks brings over 30 years of experience in the biopharma industry, previously serving as Chief Commercial Officer at Applied Therapeutics, Inc. and holding various leadership positions at major pharmaceutical companies. His compensation includes an annual salary of $480,000 and a potential performance bonus. Additionally, he will receive a grant of 11,000 restricted stock units vesting over four years, as part of an inducement award. Mr. Hooks is also eligible for the Company's Severance and Change in Control Plan. This strategic appointment aims to bolster the Company's commercial operations and leadership.
- : SEC 8-K (8.01):
- : Spruce Biosciences Appoints Daven Mody as Senior VP of Regulatory and Quality, Bruno Gagnon as Senior VP of Clinical Development Operations
- : SEC 8-K (1.01): On January 7, 2026, Spruce Biosciences, Inc. entered into a Loan and Security Agreement with Avenue Capital Management II, L.P. as administrative agent and Avenue Venture Opportunities Fund II, L.P. as lender. The agreement provides for term loans totaling up to $50 million, with initial funding of $15 million expected within 5 business days. Additional funding tranches are contingent on the achievement of regulatory milestones related to a treatment for Sanfilippo Syndrome Type B. The loans are secured by the company's assets and bear interest at a minimum of 5.25% plus the prime rate, with a maturity date of July 1, 2029, allowing for interest-only payments initially.
- : SEC 8-K (5.02):
- : SEC 8-K (5.02): On December 11, 2025, Dr. Tiba Aynechi resigned from the board of directors and as Chair of the Compensation Committee of Spruce Biosciences, Inc. This departure was effective immediately and was not due to any disagreements with the company. Additionally, the board approved a significant Option Repricing on the same day, reducing the exercise price of certain outstanding stock options to $104.13 per share. This repricing affects options granted under the 2016 and 2020 Equity Incentive Plans, with specific retention conditions for option holders to be eligible for the reduced price, contingent upon continuous service and other corporate events. This restructuring may influence employee retention and executive compensation strategies within the company.
Spruce Biosciences funding history
| Date | Round | Amount |
|---|---|---|
| Oct 2025 | Venture | $50.0M |
| Feb 2023 | Venture | $53.6M |
| Feb 2020 | Venture | $88.0M |
| Feb 2020 | Series B | $88.0M |
Leadership
- Alexis Howerton, Founder
- Anna Fath, Associate Marketing Director
- Daniel Spiegelman, Director
- Dina Chaya, Director
- Bali Muralidhar, Director
- Javier Szwarcberg, Executive Officer, Director
- RICHARD KING, Executive Officer, Director
- NIALL O'DONNELL, Director
- MICHAEL GREY, Director
- CAMILLA SIMPSON, Director
Verified email and direct lines for Spruce Biosciences’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Spruce Biosciences files 3 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Spruce Biosciences in the news
- Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates - Business Wire (Mar 09, 2026)
- Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates - Business Wire (Aug 12, 2026)
- Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™ - Business Wire (Jan 28, 2026)
- Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS Symposium - Business Wire (Jun 08, 2026)
- Spruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) - Business Wire (Apr 15, 2025)
- Spruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - Business Wire (Sep 08, 2026)
- Spruce Biosciences to Participate in Upcoming Conferences in June - Business Wire (May 27, 2026)
- Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB) - Business Wire (Oct 06, 2025)
Companies similar to Spruce Biosciences
- Corvex Legacy Holdings · Biotechnology
- BIOVIE INC. · Biotechnology
- Aerska · Biotechnology
- Cornell Technologies · Biotechnology
- Nuance Labs · Biotechnology
About Spruce Biosciences: questions and answers
What does Spruce Biosciences do?
Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company aims to address significant unmet medical needs through innovative treatment solutions. Spruce has a particular focus on rare diseases and is committed to serving patient communities. They are known for their work in enzyme replacement
Where is Spruce Biosciences headquartered?
Spruce Biosciences is headquartered in South San Francisco, California, United States.
How many employees does Spruce Biosciences have?
Spruce Biosciences has about 20 employees.
Has Spruce Biosciences raised funding?
Yes. Fundz has recorded 4 funding events for Spruce Biosciences. The most recent, $50.0M, was in Oct 2025.
Who leads Spruce Biosciences?
Alexis Howerton is a Founder at Spruce Biosciences.
What is the latest news on Spruce Biosciences?
On Jul 27, 2026, SEC 8-K (5.02): On July 27, 2026, Spruce Biosciences, Inc. appointed Adrian Quartel, M.D., FFPM, as the Chief Medical Officer, replacing Dr. Kirk Ways, who will remain on the Board of Directors. Dr. Quartel is a seasoned professional with over 25 years of experience in the pharmaceutical industry, n
Is Spruce Biosciences a public company?
Yes. Spruce Biosciences is publicly traded under the ticker SPRB.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy